10.1371/journal.pone.0157741
Karin A. Vallega
Karin A.
Vallega
NingNing Liu
NingNing
Liu
Jennifer S. Myers
Jennifer
S. Myers
Kaixian Yu
Kaixian
Yu
Qing-Xiang Amy Sang
Qing-Xiang Amy
Sang
Elevated Resistin Gene Expression in African American Estrogen and Progesterone Receptor Negative Breast Cancer
Public Library of Science
2016
AA breast cancer patients
Results Resistin RNA
breast cancer biomarker
African American Estrogen
breast cancer risk
subtype
AA breast cancer
III estrogen receptor
gene expression analysis
resistin expression
resistin gene expression
Breast cancer prognosis
AA women
breast cancer
Conclusion Resistin gene expression levels
breast cancer tissues
CA women
Cancer Genome Atlas
Breast Cancer Introduction
resistin expression levels
Elevated Resistin Gene Expression
breast cancer gene expression data
resistin levels
2016-06-17 05:24:07
Dataset
https://plos.figshare.com/articles/dataset/Elevated_Resistin_Gene_Expression_in_African_American_Estrogen_and_Progesterone_Receptor_Negative_Breast_Cancer/3445322
<div><p>Introduction</p><p>African American (AA) women diagnosed with breast cancer are more likely to have aggressive subtypes. Investigating differentially expressed genes between patient populations may help explain racial health disparities. Resistin, one such gene, is linked to inflammation, obesity, and breast cancer risk. Previous studies indicated that resistin expression is higher in serum and tissue of AA breast cancer patients compared to Caucasian American (CA) patients. However, resistin expression levels have not been compared between AA and CA patients in a stage- and subtype-specific context. Breast cancer prognosis and treatments vary by subtype. This work investigates differential resistin gene expression in human breast cancer tissues of specific stages, receptor subtypes, and menopause statuses in AA and CA women.</p><p>Methods</p><p>Differential gene expression analysis was performed using human breast cancer gene expression data from The Cancer Genome Atlas. We performed inter-race resistin gene expression level comparisons looking at receptor status and stage-specific data between AA and CA samples. DESeq was run to test for differentially expressed resistin values.</p><p>Results</p><p>Resistin RNA was higher in AA women overall, with highest values in receptor negative subtypes. Estrogen-, progesterone-, and human epidermal growth factor receptor 2- negative groups showed statistically significant elevated resistin levels in Stage I and II AA women compared to CA women. In inter-racial comparisons, AA women had significantly higher levels of resistin regardless of menopause status. In whole population comparisons, resistin expression was higher among Stage I and III estrogen receptor negative cases. In comparisons of molecular subtypes, resistin levels were significant higher in triple negative than in luminal A breast cancer.</p><p>Conclusion</p><p>Resistin gene expression levels were significantly higher in receptor negative subtypes, especially estrogen receptor negative cases in AA women. Resistin may serve as an early breast cancer biomarker and possible therapeutic target for AA breast cancer.</p></div>